Merck Anti-Emetic Emend Adds Postoperative Nausea Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Emend represents the first new class of therapy for the management of PONV in more than 10 years, Merck says.
You may also be interested in...
FDA “Approvable” Letter Requests Validation, Stability Data For Merck’s Emend IV
Firm will respond “within the next few months” to May 3 letter, Merck tells “The Pink Sheet” DAILY.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13